- alias::
  ICD-11_Code::
  tags:: disease
- #definition Blood accumulation in the anterior chamber of the eye is called Hyphaema
- ## Etiology
  background-color:: blue
  #eye-prof-card
	- ### Causative Agents
		- Trauma (blunt or penetrating injury to the eye)
			- Opthalmic Trauma
			- Ocular Surgeries like trabeculectomy
		- Inflammatory
			- Herpetic uveitis
		- Neoplastic
			- Retinoblastoma
		- Neovascularization of the iris
			- Diabetes Mellitus
			- Neovascularization of the iris
				- DM
				- Neovascular Glaucoma
		- Systemic
			- Haemophilia
			- Purpura
			- Idiopathic
	- ### Risk Factors
		- Trauma (sports injuries, assaults, accidents)
		- Anticoagulant use (warfarin, aspirin)
		- Blood dyscrasias (sickle cell disease, hemophila)
		- Neovascularization (diabetic retinopathy, central retinal vein occlusion)
- ## Epidemiology
  background-color:: blue
	- ### Incidence
		- ~20 oer 100,000 anually
	- ### Prevalence
		- ### Demographics
			- More common in males (3:1 male-to-female ration)
			- Peak incidence in children and young adults (trauma-related)
	- ### Geographic Distribution
		- Higher in regions with limited eye protection (sports, occupational hazards)
- ## Pathophysiology
  background-color:: blue
	- ### Mechanism of Disease
		- Rupture of iris or. ciliary blood vessels -> blood accumulation in anterior chamber
		- Impaired aqueous humor outflow -> elevated intraocular pressure (IOP)
	- ### Affected Systems/Organs
		- Eye (anterior chamber, trabecular meshwork, cornea)
- ## Clinical Features
  background-color:: blue
	- ### Clinical Presentation
		- #### Symptoms
			- History of Blunt Trauma to the Eye
			- Pain
			- Blurred vision
			- Photophobia
		- #### Signs
			- Visible blood in anterior chamber (graded I-IV based on severity)
			- Elevated IOP (if severe)
			- Corneal staining (if recurrent)
	- ### Stages or Classification
		- Grade I : <1/3 anterior chamber filled
		- Grade II : 1/3-1/2 filled
		- Grade III : > 1/2 filled
		- Grade IV : Total Hyphema ("8 ball byphema")
		  *appears black*
- ## Diagnosis
  background-color:: blue
	- ### Diagnostic Criteria
		- Clinical Diagnosis : Clinical Observation of blood in anterior chamber
		- History of trauma or underlying condition
	- ### Investigation
		- ### Establishing Diagnosis
			- Slit lamp examination
			- Gonioscopy (if no trauma history)
			- Ultrasound biomicroscoy (if cornea opaque)
		- ### Ruling Out Differential Diagnosis
			- |DD|Ruling Out|
			  |--|--|
			  |Uveitis|No layered blood, cells/flare present|
			  |Vitreous hemorrhage| Blood in posterior segment|
			  |Corneal abrasion|Fluorescein staining, no hyphema|
		- ### General Assessment
			- IOP measurement
			- Sickle cell testing (if applicable) (africa)
			- Coagulation Profile
- ## Management and Treatment
  background-color:: blue
	- ### Medical Treatment
		- Topical steroids (prednisolone acetate)
		- Tranexamic Acid (Fibrinolytic)
		- Cycloplegics (atropine)
		- IOP lowering agents (timolol eye drop, acetazolamide oral)
	- ### Surgical Options
		- Anterior chamber washout (if IOP uncontrolled, staining)
		- Limbal incision and clot removal (if 8 ball hyphema)
	- ### Lifestyle and Dietary Recommendations
		- Complete bed rest
		- Head elevation (30-45ยบ)
		- Avoid all NSAIDs especially aspirin(if for pain)
	- ### Follow-up
		- Daily monitoring for rebleeding (peak risk at 3-5 days)
- ## Prognosis
  background-color:: blue
	- ### Expected Course
		- #### With Treatment
			- Resolves in 5-7 days (Grade I-II)
		- #### Without Treatment
			- ##### Possible Complications
				- Corneal blood staining
				- Glaucoma
				- Optic atrophy
			- ##### Long-Term Effects
				- Vision loss (if IOP uncontrolled)
	- ### Survival Rates
		- #### With Treatment
		- #### Without Treatment
	- ### Quality of Life Considerations
		- Activity restrictions (avoid contact sports)
- ## Prevention
  background-color:: blue
	- ### Health Education
		- Eye protection (sports, hazardous work)
	- ### Community Approach
		- Awareness campaigns (wear goggles)
	- ### Screening Programs
		- Sickle cell screening in high risk populations
	- ### Lifestyle Modifications
- ## Patient Education and Support
  background-color:: blue
	- ### Educational Resources
	- ### Support Groups
	- ### Counseling Options
- ## Recent Research and Developments
  background-color:: blue
	- ### Ongoing Clinical Trials
		- Fibrinolytic therapy for clot resolution
	- ### Recent Advances
		- Microinvasive glaucoma surgery (MIGS) for secondary glaucoma
- ## Key Literature
  background-color:: blue
- ## Guidelines and Protocols
  background-color:: blue